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AbstrACt
Introduction Sepsis is a leading cause of mortality in 
critically ill patients. Recently, it has been recognised that 
sex may contribute to a differential risk for developing 
sepsis and it remains uncertain if the prognosis of sepsis 
varies between the sexes. The aim of this systematic 
review is to summarise the available evidence to assess 
the role of sex as a prognostic factor in patients with 
sepsis managed in the intensive care unit (ICU).
Methods and analysis This is a systematic review 
protocol of prognostic studies of sex in patients with 
sepsis managed in the ICU. The primary outcomes include 
all- cause hospital mortality and all- cause hospital mortality 
during the first 28 days. The secondary outcomes include 
all- cause hospital mortality during the first 7 days and 
all- cause mortality at 1 year. We will conduct a search 
strategy based on the population (sepsis), the prognostic 
factor (sex), the outcome of interest (mortality) and 
prognostic study methods. We will search in the following 
databases up to December 2019: MEDLINE Ovid (from 
1976), Embase Elsevier (from 1974), Web of Science 
and two trial registries. We will impose no language 
restrictions. Two authors will independently screen titles, 
abstracts and full- text articles for eligibility of studies, and 
subsequently extract data. Two authors will independently 
assess the risk of bias of each study using the Quality 
in Prognostic Studies (QUIPS) tool. If possible, we will 
carry out a meta- analysis to provide a pooled prognostic 
effect estimate for each outcome. We will use the Grading 
of Recommendations Assessment, Development and 
Evaluation system to assess the quality of evidence.
Ethics and dissemination Ethical approval will not be 
required. Findings from this review will be reported in a 
peer- reviewed scientific journal. Additionally, the results 
will be disseminated at conferences and in the mass 
media.
PrOsPErO registration number CRD42019145054.
IntrOduCtIOn
Sepsis is currently defined as life- threatening 
organ dysfunction resulting from a dysregu-
lated host response to inflammation.1 Sepsis 
is a major health problem with a worldwide 
incidence of about 1 case per 1000 patients, 
making it the main cause of admission to an 
intensive care unit (ICU) in high- income 
countries.2 3 Moreover, despite advances in 
healthcare, sepsis remains a leading cause 
of death every year and is the most common 
cause of death within the ICU.4–6
Sepsis is a heterogeneous disease affecting 
both male and female individuals.7 Recently, 
it has been recognised that sex may contribute 
to a differential risk for developing sepsis; and 
it remains uncertain if the prognosis of sepsis 
varies between the sexes.8–14 Prognosis factors 
are relevant in clinical care as they can iden-
tify risk groups in which clinical practice may 
be tailored to the aim of reducing morbidity 
and mortality.15 The aim of this systematic 
review is to summarise the available evidence 
to assess the role of sex as a prognostic factor 




We registered the protocol with an Inter-
national Prospective Register of Systematic 
Reviews (PROSPERO) on 12 November 
2019. Possible amendments will be updated 
on PROSPERO. The protocol is reported 
strengths and limitations of this study
 ► To our knowledge, this systematic review will be the 
first addressing sex as a prognostic factor for sep-
sis and its findings may help to stratify patients for 
treatment.
 ► This systematic review will examine mortality out-
comes, which are critical for patients and decision 
making.
 ► There may be challenges for meta- analysing the re-
sults due to heterogeneity among primary studies.
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according to the recommendations of the Preferred 
Reporting Items for Systematic Review and Meta- Analysis 
(PRISMA) Protocols statement.16 The review will be 
reported according to the PRISMA statement.17
Eligibility criteria
Type of studies
We will include experimental studies, randomised or not, 
and any observational study investigating the prognostic 
significance of sex in adults with sepsis managed in the 
ICU. Regarding prognostic factor studies, we will only 
include phase II confirmatory studies.
Type of participants
Adults (male and female individuals, which allow deter-
mining the role of sex) aged ≥16 years with a diagnosis 
of sepsis. We will accept the study authors’ definition of 
sepsis and septic shock. For a study to be eligible, the 
sepsis must be managed in an ICU. Studies including 
adults, children and/or adolescents will be eligible if 
adults represent >80% of the study sample.
Type of prognostic factors
We will include studies that assess sex as a prognostic 
factor. We will accept any assessment of sex as provided 
by the study authors. The concepts of sex and gender 
are distinct. Sex is a biological characteristic and gender 
refers to the socially constructed roles, behaviours and 
identities of women, men and gender- diverse individ-
uals.18 This review will not assess the association between 
gender and the outcomes of patients with sepsis in the 
ICU.
We will assess the role of sex as a prognostic factor 
after adjustment for additional covariates. After a liter-
ature search and a consensus process with clinician 
review authors, and as suggested during peer review of 
our protocol (online supplementary appendix 1), we 
agreed on the following core set of adjustment factors: 
age, severity score (Sequential Organ Failure Assessment 
socre (SOFA), Simplified Acute Physiology Score II (SAPS 
II) or Acute Physiologic Assessment and Chronic Health 
Evaluation II (APACHE II)), comorbidities (immunosup-
pression,pulmonary diseases, cancer, liver diseases and 
alcohol dependence), non- urinary source of infection, 
inappropriate or late antibiotic coverage.19–26 We may 




 ► All- cause hospital mortality (the longest follow- up 
provided by the study authors).
 ► All- cause hospital mortality during the first 28 days.
Secondary outcomes
 ► All- cause hospital mortality during the first 7 days.
 ► All- cause mortality at 1 year.
Information sources
We will search the following databases:
 ► MEDLINE Ovid (from 1946 onwards).
 ► Embase Elsevier (from 1974 onwards).
 ► Web of Science (WoS).
search methods
The search strings will be based on terms related to the 
population (sepsis), the prognostic factor (sex), the 
outcome (mortality) and prognostic study methods.27 
For ‘sex’ we will use a search string adapted from Loren-
zetti, Moerman, Song and Stewart28–31(online supplemen-
tary appendix 2). We will not apply publication date or 
language restrictions.
Moreover, we will check the bibliographic references 
for additional relevant studies. We will also scan  Clinical-
Trials. gov ( www. clinicaltrials. gov) and the WHO Inter-
national Clinical Trials Registry Platform ( apps. who. int/ 
trialsearch/) for unpublished and ongoing studies.
Furthermore, we will search for conference abstracts of 
major critical care and infectious diseases symposia from 
2010.
1. Interscience Conference on Antimicrobial Agents and 
Chemotherapy (ICAAC); 50th edition 2010 to 59th 
edition 2019.
2. European Congress of Clinical Microbiology and In-
fectious Diseases (ECCMID); 20th edition 2010 to 29th 
edition 2019.
3. Society for Healthcare Epidemiology of America 
(SHEA): IDWeek 2012 to 2019 editions.
4. International Conference on Prevention and Infection 
Control (ICPIC): 2011, 2013, 2015, 2017, 2019
5. Society of Critical Care Medicine (SCCM): 39th edi-
tion 2010 to 48th edition 2019.
6. International Symposium on Intensive Care and Emer-
gency Medicine (ISICEM): 30th edition 2010 to 39th 
edition 2019.
7. European Society of Intensive Care Medicine (ESICM): 
2010 onwards.
Apart from that, we will contact experts on the topic to 
ask for any ongoing, missing or unreported studies.
study rECOrds
data management
We will eliminate duplicates with Endnote 7.8 reference 
management software.32 We will manage the resultant 
unique references with the online software EPPI- Reviewer 
to identify additional duplicates, select studies, build the 
data extraction templates and extract the data.33
study selection and data collection
Two of six review authors (AAM, AH, MPA, OM, RdC, PF) 
will independently screen retrieved results according to 
the best practice guidelines to determine whether they 
fulfil the eligibility criteria of this review.34 We will use a 
consensus method, and a third author (JL- A, AAM, ES) 
will be consulted if there are disagreements. We will pilot 
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eligibility criteria on a sample of references to ensure 
their reproducibility. Assessment of the eligibility of full 
texts will be undertaken similarly. Two of seven authors 
(JL- A, AAM, AH, MP, OM, RdC, PF) will independently 
extract data according to a pre- defined form and a third 
author will resolve the discrepancies (JL- A, AAM, ES). We 
will pilot the data extraction template with three studies 
to ensure its suitability. We will compare results and 
resolve discrepancies by discussion or by referring to a 
third review author.
data items
We will use CHecklist for critical Appraisal and data 
extraction for systematic Reviews of prediction Modelling 
Studies for prognostic factor (CHARMS- PF) guidance for 
data collection.35 This tool modifies the original CHARMS 
checklist for prediction model studies.36 We will extract 
the following data from each eligible study:
1. Publication date, country and setting in which the 
study was conducted.
2. Study design: experimental study or observational 
study.
3. Registration: presence of registration or protocol 
published (yes/no).
4. Sepsis definition used by authors.
5. Participant characteristics: participant description, 
eligibility criteria and details of treatment received (if 
applicable).
6. Sex definition used by authors.
7. Review outcomes reported in the study: mortality; 
type of measures (binary); follow- up period (the first 
7 days, the first 28 days and the longest follow- up pro-
vided by the study authors).
8. Missing data: attrition (quantification and reasons), 
handling of missing data by the study authors(avail-
able case analysis or imputation).
9. Analysis: univariate analysis/logistic regression/Cox 
regression/other.
10. Estimates reported between the prognostic factor 
and each review outcome: (a) unadjusted estimate: 
association between sex and mortality with no covari-
ate; (b) adjusted estimates: association/s between sex 
and mortality with at least one covariate.
11. Type of measure of association: odds ratio (OR), risk 
ratio (RR) or hazard ratio (HR).
12. List ofadjustment factors that were used. We will con-
tact authors of individual studies for additional infor-
mation if required.
Assessment of methodological quality and risk of bias
We will use the QUIPS (Quality In Prognosis Studies) 
tool to assess risk of bias.35 Two review authors will inde-
pendently assess the following six domains of the QUIPS 
tool: (1) study participation; (2) study attrition; (3) prog-
nostic factor measurement; (4) outcome measurement; 
(5) adjustment for other prognostic factors; (6) statistical 
analysis and reporting.
We will make a judgement for every criterion, using one 
of four categories (low, moderate, high risk and unclear), 
adapting the QUIPS guidelines.35 37 38 We will resolve 
disagreements by discussion, and a third author will be 
consulted if it is required.
We will evaluate the impact of risk of bias from primary 
studies by performing sensitivity analyses (see the Sensi-
tivity analyses section).
data synthesis
For each study and prognostic effect estimate, we will 
extract the measures of association reported in each 
study (OR, RR, HR) along with its standarderror (SE) 
or confidence intervals (CIs). We will transform associa-
tion measures into OR with its 95% CI in order to allow 
statistical pooling whenever adequate.39 We acknowledge 
that the studies providing the adjusted prognostic effect 
of a particular factor can differ in the set of adjustment 
factors. We will define a core set of adjustment factors for 
each review outcome.
If the study provides a set of adjustment factors that 
differ from our core set, we will meta- analyse the study 
but the estimate will be penalised as part of the risk of bias 
assessment. If the same study presents different estimates 
for the same outcome, each of them adjusted for different 
factors, we will extract the estimate that has adjusted for 
the maximum number of our key confounders for meta- 
analysis. If there are several estimations, all of them having 
adjusted for the same key confounders, we will consider 
the estimate adjusted for more confounders in total. We 
assume that this will minimise the risk of confounding 
bias in the estimation.
We plan to combine the results from individual studies 
in a meta- analysis to provide a pooled prognostic effect 
estimate for each outcome. We will carefully evaluate the 
censoring mechanisms assumed in the studies that have 
been analysed using time- to- event procedures (i.e., Cox 
proportional hazard models). If we conclude that there 
is a risk of bias due to informative censoring (e.g., when 
patients with better prognosis are discharged for the 
ICU), we will disregard HRs obtained in such studies. We 
plan to use the Hartung- Knapp- Sidik- Jonkman (HKSJ) 
method for random- effects meta- analysis. We will use 
the Cochrane statistical package Review Manager 5.3 for 
organising the text of the review, and if the meta- analysis 
is possible, we will use the metareg command in Stata 
(Stata V.15.1) for performing the meta- analysis with the 
HKSJ method.40
Heterogeneity between studies
When there are at least three studies, we will examine 
heterogeneity by calculating prediction intervals in order 
to inform how the effect varies across populations. The 
prediction interval is an index of dispersion that describes 
the range of effect sizes in which we would expect that 
the true effect size will fall.41 We will use the spreadsheet 
provided by Borenstein et al for computing the prediction 
interval.42
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If we judge that the meta- analysis is inappropriate for 
other reasons, we will not combine results and we will 
undertake a narrative analysis of studies.
To better understand the sources of heterogeneity, we 
plan to conduct the following subgroup analyses:
 ► Trials versus cohort studies versus case–control studies.
 ► Prospective studies (all the study parts were prospec-
tive) versus retrospective studies (all the study parts 
were retrospective).
Sensitivity analyses
We will undertake the following sensitivity analyses:
 ► Evaluate the impact of risk of bias from individual 
trials in the overall effect. We will consider the 
following risk of bias domains as key domains for 
the analyses: study attrition, prognostic factor meas-
urement, outcome measurement and adjustment for 
other prognostic factors.
 ► We will exclude studies with a high risk of bias in at 
least one key domain.
 ► We will exclude studies with a high or moderate risk of 
bias in at least one key domain.
 ► Assess the effect of excluding studies that have 
provided an adjusted estimate, but that did not adjust 
for all our core set of additional prognostic factors.
Publication bias
We will attempt to assess the presence of publication bias 
for each meta- analysis containing ≥10 studies by funnel 
plot representation and Peter’s test at a 10% level.43
Confidence in cumulative evidence
We will attempt to use the Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) 
approach and will present our results for each main 
outcome in a ‘Summary of findings’ table, although 
we acknowledge that the GRADE approach has not 
been widely used to assess the certainty of the evidence 
of prognostic factors.44 45 We will follow the principles 
suggested in Hughet et al and Iorio et al for prognostic 
questions.46 47 We will use GRADE profiler (GRADEpro 
GDT) for designing a ‘Summary of findings’.48
Patients and public involvement
Patients and the general public will not be involved in the 
process of conducting this systematic review. We will not 
plan to involve patients in the dissemination of the results 
of this systematic review.
Ethics and dissemination
Ethical permission is not necessary as this study summarises 
published data. This review is part of the SEXCOMPLEX 
project (Influence of sex and sex hormones on human 
chronic disorders of complex aetiology), a 2- year project 
(2017–2019) coordinated by Hospital Ramón y Cajal 
(Madrid, Spain). We shall disseminate our findings 
through peer- reviewed publication, at conferences, and 
in the mass media.
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